125 filings
Page 2 of 7
6-K
9qwni c4ldd
18 Aug 20
Capital Increase in Genmab as a Result of Employee Warrant Exercise
4:07pm
6-K
4wr7ukrh6ws3 n93sp30
12 Aug 20
Genmab Announces Financial Results for the First Half of 2020
3:22pm
6-K
2raex6na 8o0yo
31 Jul 20
Current report (foreign)
4:49pm
6-K
0fn431069t198i5
20 Jul 20
Major Shareholder Announcement
1:09pm
6-K
ttvnexy bd
16 Jul 20
Genmab Announces Net Sales of DARZALEX® for the Second Quarter of 2020
10:05am
6-K
uyvx3vsc8br5jw1
7 Jul 20
Major Shareholder Announcement
11:19am
6-K
tt1gv9p6chg nl5
6 Jul 20
Major Shareholder Announcement
1:57pm
6-K
dbe0w5lfk
6 Jul 20
Major Shareholder Announcement
1:54pm
6-K
1kt ie4tzh
1 Jul 20
Current report (foreign)
10:58am
6-K
rx49ht6
30 Jun 20
Capital Increase in Genmab as a Result of Employee Warrant Exercise
3:16pm
6-K
wodv34hgeaoezbte
29 Jun 20
Genmab Announces Very Favorable Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
12:00am
6-K
js3dfiyy35z2rreawg76
11 Jun 20
Current report (foreign)
9:40am
6-K
cctwpktx qhhx
10 Jun 20
Genmab and AbbVie Announce Broad Oncology Collaboration
7:33am
6-K
mk9et09x3f
4 Jun 20
Subcutaneous fixed-dosed formulation of DARZALEX® (daratumumab) approved in Europe for the treatment of adult patients with multiple myeloma
10:55am
6-K
wx4i2px3f ml
3 Jun 20
Current report (foreign)
4:48pm
6-K
dkw6ja3kgrj
28 May 20
Genmab Announces Positive Topline Results in Phase III ANDROMEDA Study of Daratumumab in Light-chain (AL) Amyloidosis
4:14pm
6-K
ei89l4
13 May 20
Current report (foreign)
2:47pm
6-K
jycni2f8p z4yg96
12 May 20
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2:00pm
6-K
mcltm
6 May 20
Genmab Announces Financial Results for the First Quarter of 2020
2:31pm
6-K
mbhw9d
1 May 20
Subcutaneous formulation of daratumumab, DARZALEX FASPRO™, approved by the U.S. FDA for the treatment of patients with multiple myeloma
3:02pm